Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Industrifonden in connection with its investment in InDex Pharmaceuticals
Mandate

Vinge advises Industrifonden in connection with its investment in InDex Pharmaceuticals

January 24, 2011

Vinge has advised Industrifonden in connection with its SEK 40 million investment in InDex Pharmaceuticals. InDex Pharmaceuticals develops Kappaproct, a drug developed for the treatment of severe inflammatory bowel disease. Further capital has also been raised from current shareholders, including SEB Venture Capital, which has invested an additional SEK 35 million. The financing will predominantly be used to conduct a clinical phase III trial using Kappaproct with the aim of obtaining market approval.

Vinge’s team consisted of, among others, project manager Johan Larsson and Petter Kjöllerström, who was responsible for the due diligence phase of the transaction. Johan Winnerblad was the responsible partner.

Related

Vinge has advised Accent Equity VI and the minority shareholders on their divestment of Malte Månson

Vinge has advised Accent Equity VI and the minority shareholders on their divestment of Malte Månson to Citira, a European tire management provider and portfolio company of Norvestor. Headquartered in Stockholm, Malte Månson is an independent service and repair provider for commercial vehicles and operates a network of 28 service workshop locations across Sweden, authorized by brands such as MAN, DAF, IVECO, Mercedes-Benz, Setra, VDL and EVO. Malte Månson has an annual revenue of SEK 800 million and employs over 300 full-time professionals.
June 08, 2026

Vinge advises InArea on entering into a SEK 450 million credit agreement with SEB

 InArea's new facilities agreement comprises a term loan and a revolving credit facility, replacing the company's existing facilities. The facilities agreement also includes an option to increase the lending framework through an incremental facility of up to SEK 200 million.
June 03, 2026

Vinge has advised the arrangers in connection with St1 Biokraft’s EUR 260 million financing

 Vinge has advised the arrangers, ING Bank N.V., ABN AMRO Bank N.V., DNB Bank ASA, Nordea Bank Abp, OP Corporate Bank plc, Coöperatieve Rabobank U.A., SpareBank 1 Sør-Norge ASA and Swedbank AB, in connection with St1 Biokraft AB’s EUR 260 million financing.
June 03, 2026